The role of renal denervation in the treatment of heart failure

Current Cardiology Reports

Volumn 14, Issue 3, 2012, Pages 285-292

  Sobotka, Paul A ^a,f   Krum, Henry ^b   Böhm, Michael ^c   Francis, Darrel P ^d   Schlaich, Markus P ^e  

^a MEDTRONIC INC   (United States)

^b MONASH UNIVERSITY   (Australia)

^c SAARLAND UNIVERSITY   (Germany)

^d ST MARY S HOSPITAL   (United Kingdom)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f 2015 Marywood Lane West Street ^*  (United States)

Author keywords

Angiotensin; Clinical trial; Heart failure; Kidney; Norepinephrine; Renal blood flow; Renal denervation; Sympathetic

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; MOXONIDINE; NORADRENALIN; PLACEBO;

ADRENERGIC SYSTEM; ARTERY CATHETERIZATION; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DORSAL RHIZOTOMY; DOSE RESPONSE; FUNCTIONAL ANATOMY; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY NERVE; NEPHRECTOMY; NEUROSURGERY; NONHUMAN; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSORY NERVE; SYMPATHETIC INNERVATION;

DENERVATION; HEART FAILURE; HUMANS; KIDNEY; NEURONS, AFFERENT; NEURONS, EFFERENT; NOREPINEPHRINE; RENAL CIRCULATION; SYMPATHETIC NERVOUS SYSTEM;

EID: 84861098371     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0258-x     Document Type: Review

References (50)

1. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118, 465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422-30.
2. Napoli C, Casamassimi A, Crudele V, Infante T, Abbondanza C. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. Future Cardiol. 2011;7:485-97.
3. Wencker D. Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure. Curr Heart Fail Rep. 2007;4:134-8.
4. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26:906-13.
5. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933-9.
6. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: Results in 1, 266 cases. JAMA. 1953;152:1501-4.
7. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81. This study was the first to demonstrate that catheter-based renal denervation causes substantial and sustained blood pressure reduction without serious adverse events in patients with drug-resistant hypertension.
8. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:76-155.
9. Eppel GA, Luff SE, Denton KM, Evans RG Type 1 neuropeptide Y receptors and alpha1-adrenoceptors in the neural control of regional renal perfusion. Am J Physiol. 2006;290:R331-40.
10. DiBona GF, Sawin LL. Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am JPhysiol. 1991;260(2 Pt 2):R298-305.
11. Zanchetti AS. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation. 1977;56:691-8.
12. Osborn JL, Dibona GF, Thames MD. Beta-l receptor mediation of renin secretion. elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther. 1981;216:265-9.
13. Holmer S, Rinne B, Eckardt KU, Le Hir M, Schricker K, Kaissling B, Riegger G, Kurtz A. Role of renal nerves for the expression of renin in adult rat kidney. Am J Physiol. 1994;266:F738-45.
14. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659-82.
15. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol. 1983;245:F1-F14.
16. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens. 1984;2:349-59.
17. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-9.
18. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-21.
19. Ramchandra R, Hood SG, Denton DA, Woods RL, McKinley MJ, McAllen RM, May CN. Basis for the preferential activation of cardiac sympathetic nerve activity in heart failure. Proc Natl Acad Sci USA. 2009;106:924-8. This study was the first to directly record renal sympathetic nerve activity in heart failure. Heart failure was induced in sheep by 6 to 8 weeks of rapid ventricular pacing, and there was a significant increase in integrated nerve activity in both the renal and cardiac sympathetic nerves.
20. Creager MA. Baroreceptor reflex function in congestive heart failure. Am J Cardiol. 1992;69:10G-5G
21. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension. 2006;48:1005-11.
22. Schultz HD, Li YL, Ding Y Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension. 2007;50:6-13.
23. Ponikowski P, Chua TP, Anker SD, Francis DP, Doehner W, Banasiak W, Poole-Wilson PA, Piepoli MF, Coats AJ. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation. 2001;104:544-9.
24. Kon V. Neural control of renal circulation. Miner Electrolyte Metab. 1989;15:33-43.
25. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr. 1989;67:858-64.
26. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514-7.
27. Villarreal D, Freeman RH, Johnson RA, Simmons JC. Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol. 1994;266(5 Pt 2):R1599-604.
28. Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, Inoue H. Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels. 2002;16:51-6.
29. Souza DR, Mill JG, Cabral AM. Chronic experimental myocardial infarction produces antinatriuresis by a renal nerve-dependent mechanism. Braz J Med Biol Res. 2004;37:285-93.
30. Pettersson A, Hedner J, Hedner T. Renal interaction between sympathetic activity and ANP in rats with chronic ischaemic heart failure. Acta Physiol Scand. 1989;135:487-92.
31. Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol. 2011;300:F31-9.
32. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med. 1988;319:1065-72.
33. Fung JW, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, Nicholls MG, Sanderson JE. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 2003;92:406.
34. Galiwango PJ, McReynolds A, Ivano J, Chan CT, Floras JS. Activity with ambulation attenuates diuretic responsiveness in chronic heart failure. J Card Fail. 2011;17:797-803. This study showed that an increase in sympathetic tone influences the response to furosemide in patients with heart failure. Intravenous furosemide (75% of the usual oral morning dose) was administered to 9 patients with stable heart failure (NYHA class II-III, LVEF < 40%) in both supine (90 minutes recumbency) and upright postures (90 minutes sitting and treadmill walking). Sodium excretion and urine volume 90 minutes after furosemide were attenuated in the upright compared with the supine posture, whereas plasma norepinephrine and renin activity were increased.
35. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ. MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-67.
36. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ. Moxonidine Safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002;105:1797-803.
37. Kopp UC. Renorenal reflexes: neural and functional responses. Fed Proc. 1985;44:2834-9.
38. Rieg T, Vallon V. ATP and adenosine in the local regulation of water transport and homeostasis by the kidney. Am J Physiol Regul Integr Comp Physiol. 2009;296:R419-27.
39. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation. 1997;95:1363-5.
40. Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol. 1997;10:184-7.
41. Wyss JM, Aboukarsh N, Oparil S. Sensory denervation of the kidney attenuates renovascular hypertension in the rat. Am J Physiol. 1986;250:H82-6.
42. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertension. 2002;15:717-24.
43. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-9.
44. Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209-15.
45. Schlaich MP, Sobotka PA, Krum H, Lambert EA, Esler MD. Renal sympathetic nerve ablation for the treatment of uncontrolled hypertension. N Engl J Med. 2009;361:932-4.
46. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-9. In this very important multicenter, prospective, randomized trial, patients who had a baseline systolic blood pressure of > 160 mm Hg despite treatment with three or more antihypertensive drugs were randomly allocated to renal denervation plus previous treatment (n=52) or to a control group (n=51) that maintained previous treatment alone. At 6 months of follow-up, office-based blood pressure measurements in the renal denervation group fell by an average of 32/12 mm Hg from a baseline of 178/96 mm Hg (P< 0.0001), whereas it did not differ from baseline in the control group. The results show that catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatmentresistant hypertensive patients.
47. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol. 1980;238:R353-8.
48. Arrowood JA, Goudreau E, Minisi AJ, Davis AB, Mohanty PK. Evidence against reinnervation of cardiac vagal afferents after human orthotopic cardiac transplantation. Circulation. 1995;92:402-8.
49. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-917. This study demonstrated the durability of blood pressure reduction after renal denervation. Inpatients with drug-resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in blood pressure that was sustained out to > 2 years of follow-up, without significant adverse events.
50. Grimm Jr RH, Flack JM. Alpha 1 adrenoreceptor antagonists. J Clin Hypertens. 2011;13:654-7.